Quick Answer
Mineralys Therapeutics, Inc. reported Net Income of -$154.65 million for fiscal year 2025.
Mineralys Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$154.65M | +13.0% |
| 2024 | -$177.81M | -147.3% |
| 2023 | -$71.90M | -141.3% |
| 2022 | -$29.80M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$36.93M | +34.5% | +14.7% |
| June 30, 2025 | -$43.27M | -5.5% | -2.5% |
| March 31, 2025 | -$42.21M | -34.0% | +25.1% |
| September 30, 2024 | -$56.34M | -147.5% | -37.4% |
| June 30, 2024 | -$41.01M | -237.8% | -30.2% |
| March 31, 2024 | -$31.51M | -149.9% | -38.4% |
| September 30, 2023 | -$22.76M | -240.8% | -87.5% |
| June 30, 2023 | -$12.14M | -87.4% | +3.7% |
- Mineralys Therapeutics, Inc. showed an increase of +13.0% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, Mineralys Therapeutics, Inc.’s net income has declined by 419.0% (from -$29.80 million to -$154.65 million).
- The most recent figure is from Mineralys Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: